ライフサイエンスコーパス: isocitrate

1 dehydrogenase (carboxylation of alpha-KG to isocitrate).

2 uppressed by providing the aconitase product isocitrate.

3 is much more sensitive to concentrations of isocitrate.

4 cluster proteins that metabolize citrate to isocitrate.

5 trate, homoisocitrate, or the slow substrate isocitrate.

6 Here, we report 2-vinyl-d-isocitrate (2-VIC) as a mechanism-based inactivator of M

7 arboxylic acid cycle intermediates (citrate, isocitrate, 2-oxoglutarate, succinate, fumarate, malate,

8 Exogenous isocitrate abrogated the erythroid iron restriction resp

9 f the erythroid iron restriction response by isocitrate administration corrected anemia and erythropo

10 DH1 and IDH2 catalyze the interconversion of isocitrate and 2-oxoglutarate (2OG).

11 extension in C. elegans, reversibly converts isocitrate and acetyl-CoA to succinate, malate, and CoA.

12 nt with reduced oxidative decarboxylation of isocitrate and acquisition of the ability to convert alp

13 ttributed to the competitive binding between isocitrate and alphaKG, which is made more favorable for

14 The mitochondrial export of isocitrate and engagement with cytosolic isocitrate dehy

15 se assays demonstrated the presence of eight isocitrate and four AMP binding sites for the wild-type

16 Mtb's ICLs are catalytically bifunctional isocitrate and methylisocitrate lyases required for grow

17 ction, with the ability to form alphaHG from isocitrate and NADP(+).

18 the chiral imidazolium hosts toward citrate, isocitrate and the two enantiomers of malate have been s

19 ta, whose activities were regulated by iron, isocitrate, and erythropoietin.

20 mmonly found in AML reduces the affinity for isocitrate, and increases the affinity for NADPH and alp

21 yglutarate, citrate, oxaloacetate, pyruvate, isocitrate, and lactate using a 8-min run time in cancer

22 ctivation occurs only when concentrations of isocitrate are elevated.

23 homoisocitrate as a substrate, but not with isocitrate as a substrate, because the oxidative decarbo

24 With isocitrate as the substrate, the observed primary deuter

25 Feeding of isocitrate as well as the nonmetabolizable citrate analo

26 ing it to react with carbon dioxide and form isocitrate, as occurs in the wild-type enzyme.

27 ffect a single amino acid located within the isocitrate binding site (R132 of IDH1 and the analogous

28 dictions that the enzyme would contain eight isocitrate binding sites, four NAD(+) binding sites, and

29 Cys-150 residues and to half-site binding of isocitrate, but that a form of negative cooperativity ma

30 pathway, involving the mitochondrial citrate/isocitrate carrier and the cytosolic NADP-dependent isoc

31 siRNA-mediated suppression of ICDc, citrate/isocitrate carrier, or Kv2.2 expression impaired GSIS, a

32 Isotope tracing revealed that in spheroids, isocitrate/citrate produced reductively in the cytosol c

33 odel in which a key function of the pyruvate-isocitrate cycle is to maintain levels of Kv2.2 expressi

34 Recent studies have shown that the pyruvate-isocitrate cycling pathway, involving the mitochondrial

35 agogues, involving flux through the pyruvate/isocitrate cycling pathway.

36 Here we demonstrate that pyruvate-isocitrate cycling regulates expression of the voltage-g

37 direction of the normal reaction (alphaKG to isocitrate), dead-end inhibition studies suggest that wi

38 harboring a mutation in the gene coding for isocitrate dehydrogenase ( IDH).

39 tion cryo-EM structures of the cancer target isocitrate dehydrogenase (93 kDa) and identify the natur

40 ase and to stimulate the reverse reaction of isocitrate dehydrogenase (carboxylation of alpha-KG to i

41 The downstream isocitrate dehydrogenase (citC) gene appears to be part

42 of isocitrate and engagement with cytosolic isocitrate dehydrogenase (ICDc) may be one key pathway,

43 ate carrier and the cytosolic NADP-dependent isocitrate dehydrogenase (ICDc), is involved in control

44 (via isocitrate lyase) or the TCA cycle (via isocitrate dehydrogenase (ICDH) activity) and we sought

45 Mutant isocitrate dehydrogenase (IDH) 1 and 2 proteins alter th

46 1 and aminopeptidase), inhibitors of mutated isocitrate dehydrogenase (IDH) 1 and IDH2, antibody-base

47 associated with disease progression such as isocitrate dehydrogenase (IDH) 1, IDH2, EZH2, serine/arg

48 Cit2 and reduced expression of NAD-specific isocitrate dehydrogenase (Idh) and aconitase (Aco1) in p

49 Mutations in isocitrate dehydrogenase (IDH) are the most prevalent ge

50 The discovery of somatic mutations in the isocitrate dehydrogenase (IDH) enzymes through a genome-

51 by the discovery of mutations involving the isocitrate dehydrogenase (IDH) enzymes.

52 activity for grading and characterization of isocitrate dehydrogenase (IDH) gene mutation status of g

53 ne promoter and the mutational status of the isocitrate dehydrogenase (IDH) gene were determined.

54 Isocitrate dehydrogenase (IDH) genes 1 and 2 are frequen

55 Somatic mutations in the isocitrate dehydrogenase (IDH) genes IDH1 and IDH2 occur

56 discovery of mutations in the genes encoding isocitrate dehydrogenase (IDH) has uncovered a critical

57 terozygous mutations in the metabolic enzyme isocitrate dehydrogenase (IDH) in subsets of cancers, in

58 The human NAD-dependent isocitrate dehydrogenase (IDH) is a heterotetrameric mit

59 Isocitrate dehydrogenase (IDH) is a reversible enzyme th

60 Among a number of novel genes, isocitrate dehydrogenase (IDH) is recurrently mutated in

61 Mutations of the isocitrate dehydrogenase (IDH) metabolic enzymes IDH1 an

62 stigation of metabolic pathways disturbed in isocitrate dehydrogenase (IDH) mutant tumors revealed th

63 s caused by recurrent mutations, such as the isocitrate dehydrogenase (IDH) mutations found in 15% of

64 Cancer-associated isocitrate dehydrogenase (IDH) mutations produce the met

65 ation in a subset of glioblastomas harboring isocitrate dehydrogenase (IDH) mutations, but metabolic

66 associated with MYC signaling, but not with isocitrate dehydrogenase (IDH) mutations, suggesting a d

67 The tricarboxylic acid cycle NAD+-specific isocitrate dehydrogenase (IDH) of Saccharomyces cerevisi

68 mine the effects of large-scale variation in isocitrate dehydrogenase (IDH) or glucose-6-phosphate de

69 that shows how robust behavior arises in the isocitrate dehydrogenase (IDH) regulatory system of Esch

70 drogenase (SDH), fumarate hydratase (FH) and isocitrate dehydrogenase (IDH), advancing and challengin

71 We dissected these influences in isocitrate dehydrogenase (IDH)-mutant gliomas by combini

72 ta-N-acetylglucosamine transferase (OGT) and isocitrate dehydrogenase (IDH).

73 ide adenine dinucleotide phosphate-dependent isocitrate dehydrogenase (IDH)1 and IDH2 frequently aris

74 Oncogenic isocitrate dehydrogenase (IDH)1 and IDH2 mutations at th

75 imaging-defined invasive phenotypes of both isocitrate dehydrogenase (IDH-1)-mutated and IDH-1 wild-

76 Mutations of genes encoding isocitrate dehydrogenase (IDH1 and IDH2) have been recen

77 utarate (2HG), generated by mutated forms of isocitrate dehydrogenase (IDH1 and IDH2), reduces the ex

78 Mutations in the cytosolic NADP(+)-dependent isocitrate dehydrogenase (IDH1) occur in several types o

79 rboxylated by the NADPH-linked mitochondrial isocitrate dehydrogenase (IDH2) to form isocitrate, whic

80 B, encoding the beta-subunit of NAD-specific isocitrate dehydrogenase (NAD-IDH, or IDH3), which is be

81 We measured tissue levels of NADP-linked isocitrate dehydrogenase (NADP-ICDH), glucose-6-phosphat

82 NADP-specific isocitrate dehydrogenase (NADP-IDH, or IDH2), an enzyme

83 termediates reveals the reversibility of the isocitrate dehydrogenase + aconitase reactions, even in

84 Mutations in the metabolic enzymes isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) are frequ

85 tive carboxylation of alpha-ketoglutarate by isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) was recen

86 Mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 are among the

87 1 was exclusive to tumors carrying wild-type isocitrate dehydrogenase 1 (IDH1) and IDH2 genes and was

88 Recurrent mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 have been ide

89 sue of Blood, Shi et al describe the role of isocitrate dehydrogenase 1 (idh1) and idh2 in developmen

90 Mutations in metabolic enzymes, including isocitrate dehydrogenase 1 (IDH1) and IDH2, in cancer st

91 Mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydro

92 Monoallelic point mutations in cytosolic isocitrate dehydrogenase 1 (IDH1) and its mitochondrial

93 Mutations in the enzyme cytosolic isocitrate dehydrogenase 1 (IDH1) are a common feature o

94 Mutations of isocitrate dehydrogenase 1 (IDH1) are frequently found i

95 Gain-of-function mutations in isocitrate dehydrogenase 1 (IDH1) are key drivers of hem

96 Here, we characterize isocitrate dehydrogenase 1 (IDH1) as a transcriptional t

97 in HuR-deficient PDAC cell lines identified isocitrate dehydrogenase 1 (IDH1) as the sole antioxidan

98 Mutation in isocitrate dehydrogenase 1 (IDH1) at R132 (IDH1(R132MUT)

99 Somatic mutations of isocitrate dehydrogenase 1 (IDH1) at R132 are frequently

100 Mutant isocitrate dehydrogenase 1 (IDH1) catalyzes the producti

101 Isocitrate dehydrogenase 1 (IDH1) catalyzes the reversib

102 Mutations of the isocitrate dehydrogenase 1 (IDH1) gene are among the mos

103 Gain-of-function mutations of the isocitrate dehydrogenase 1 (IDH1) gene are among the mos

104 The recent identification of isocitrate dehydrogenase 1 (IDH1) gene mutations in glio

105 Hotspot mutations in the isocitrate dehydrogenase 1 (IDH1) gene occur in a number

106 Two mutant forms (R132H and R132C) of isocitrate dehydrogenase 1 (IDH1) have been associated w

107 nd recurrent mutations in the active site of isocitrate dehydrogenase 1 (IDH1) in 12% of GBM patients

108 Isocitrate dehydrogenase 1 (IDH1) is mutated in various

109 Somatic mutation of isocitrate dehydrogenase 1 (IDH1) is now recognized as t

110 anscripts were found in GBMs irrespective of isocitrate dehydrogenase 1 (IDH1) mutation status.

111 Absence of isocitrate dehydrogenase 1 (IDH1) mutation, asymptomatic

112 Isocitrate dehydrogenase 1 (IDH1) mutations occur in mos

113 Arg132 of the cytoplasmic NADP(+)-dependent isocitrate dehydrogenase 1 (IDH1) occur frequently in gl

114 exhibit gain-of-function mutations in either isocitrate dehydrogenase 1 (IDH1) or IDH2.

115 dromes, at least one tumor has a mutation in isocitrate dehydrogenase 1 (IDH1) or in IDH2, 65% of whi

116 Mutations in cytosolic isocitrate dehydrogenase 1 (IDH1) or its mitochondrial h

117 The human, cytosolic enzyme isocitrate dehydrogenase 1 (IDH1) reversibly converts is

118 Here we show that mutation of a single gene, isocitrate dehydrogenase 1 (IDH1), establishes G-CIMP by

119 Mutation at the R132 residue of isocitrate dehydrogenase 1 (IDH1), frequently found in g

120 One potential drug target is isocitrate dehydrogenase 1 (IDH1), which is mutated in m

121 that can modulate the activity of the enzyme isocitrate dehydrogenase 1 (IDH1).

122 se reverse transcriptase (TERT) promoter and isocitrate dehydrogenase 1 (IDH1).

123 Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key

124 Cancer-associated point mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) confer

125 zygously expressed single-point mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2, respect

126 Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) have been disc

127 Mutations in the genes encoding isocitrate dehydrogenase 1 and 2 (IDH1/2) occur in a var

128 Oncogenic mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) occur in sever

129 aking is that patients with mutations in the isocitrate dehydrogenase 1 and 2 (IDH1/2) oncogenes are

130 Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2), are present i

131 Mutations in IDH1 and IDH2 (encoding isocitrate dehydrogenase 1 and 2) drive the development

132 ers of gliomagenesis, including mutations in isocitrate dehydrogenase 1 and the NF-kappaB pathway, an

133 IV glioma) revealed somatic mutations of the isocitrate dehydrogenase 1 gene (IDH1) in a fraction of

134 Isocitrate dehydrogenase 1 mutations drive human gliomag

135 rganization 2007 tumor grade, histology, and isocitrate dehydrogenase 1 R132H mutational status.

136 ade gliomas with mutations in IDH1 (encoding isocitrate dehydrogenase 1), we studied paired tumor sam

137 orme that identified IDH1, the gene encoding isocitrate dehydrogenase 1, as target for cancer-driving

138 With DESI MS, we identify isocitrate dehydrogenase 1-mutant tumors with both high

139 e (R-2HG), produced at high levels by mutant isocitrate dehydrogenase 1/2 (IDH1/2) enzymes, was repor

140 Gliomas harboring mutations in isocitrate dehydrogenase 1/2 (IDH1/2) have the CpG islan

141 d hematopoietic differentiation in AML after isocitrate dehydrogenase 1/2 mutation and 2-hydroxygluta

142 levels in cancer cells with gain-of-function isocitrate dehydrogenase 1/2 mutations.

143 g genetic anchor to drive patient selection (isocitrate dehydrogenase 1/2, Enolase 2).

144 pecies (ROS) by deacetylating and activating isocitrate dehydrogenase 2 (IDH2) and superoxide dismuta

145 We show that downregulation of isocitrate dehydrogenase 2 (IDH2) and TET family enzymes

146 Mitochondrial isocitrate dehydrogenase 2 (IDH2) converts NADP(+) to NA

147 The mitochondrial matrix protein isocitrate dehydrogenase 2 (IDH2) is a major source of N

148 ochondrial superoxide dismutase 2 (SOD2) and isocitrate dehydrogenase 2 (IDH2) observed in untreated

149 Recurrent mutations in isocitrate dehydrogenase 2 (IDH2) occur in approximately

150 Recurrent mutations at R140 and R172 in isocitrate dehydrogenase 2 (IDH2) occur in many cancers,

151 ons in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) occur in most grade 2

152 and colleagues demonstrate the mutations in isocitrate dehydrogenase 2 (IDH2), commonly found in acu

153 tly deacetylates and activates mitochondrial isocitrate dehydrogenase 2 (Idh2), leading to increased

154 antioxidant system through the regulation of isocitrate dehydrogenase 2 (Idh2).

155 of unfavorable outcome, such as mutations in isocitrate dehydrogenase 2 (IDH2-R172) and overexpressio

156 rate-limiting tricarboxylic acid cycle (TCA) isocitrate dehydrogenase 2 and superoxide dismutase 2, c

157 findings demonstrate that MitEpac1 inhibits isocitrate dehydrogenase 2 via the mitochondrial recruit

158 which in turn decreased expression of IDH2 (isocitrate dehydrogenase 2).

159 nd that the aberrant expression of wild-type isocitrate dehydrogenase 3alpha (IDH3alpha), a subunit o

160 rogenase, 2-oxoxglutarate dehydrogenase, and isocitrate dehydrogenase activities of the Krebs cycle i

161 hypoxia elicited both aconitase and NADP(+)-isocitrate dehydrogenase activity losses.

162 Hepatic isocitrate dehydrogenase activity was also decreased, wh

163 ssion changes of some metabolic genes (e.g., isocitrate dehydrogenase and fumarate hydratase) may enh

164 so investigated inhibitors of NADP-dependent isocitrate dehydrogenase and mitochondrial citrate expor

165 was consistent with allosteric inhibition of isocitrate dehydrogenase by P-enolpyruvate.

166 e production of 2-hydroxyglutarate by mutant isocitrate dehydrogenase enzymes, we can observe metabol

167 Mechanistically, isocitrate dehydrogenase expression and the production o

168 Mutations in the isocitrate dehydrogenase gene (IDH1) were recently descr

169 with glioma harbor specific mutations in the isocitrate dehydrogenase gene IDH1 that associate with a

170 Mutations in the isocitrate dehydrogenase genes (IDH1/2) occur often in d

171 glioma-associated mutations into the NADP(+ )isocitrate dehydrogenase genes (IDP1, IDP2, IDP3) in Sac

172 Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 are among t

173 occurring mutations in the NADP(+)-dependent isocitrate dehydrogenase genes IDH1 and IDH2 These mutat

174 e chromatin architecture at the promoters of isocitrate dehydrogenase genes to promote transcription

175 Here, we report that the isocitrate dehydrogenase IDH1 is the most strongly upreg

176 .35 million compounds against mutant (R132H) isocitrate dehydrogenase IDH1 led to the identification

177 Ps harbored hotspot mutations at R172 of the isocitrate dehydrogenase IDH2, of which 8 of 10 displaye

178 Yeast NAD(+)-specific isocitrate dehydrogenase is an allosterically regulated

179 Isocitrate dehydrogenase is mutated at a key active site

180 hosphorylation catalyzed by the bifunctional isocitrate dehydrogenase kinase/phosphatase (IDHKP), and

181 The mass spectra also indicate the isocitrate dehydrogenase mutation status of the tumor vi

182 anine-DNA methyltransferase-methylation, and isocitrate dehydrogenase mutation status, the proportion

183 prognostic and therapeutic consequences: (a) isocitrate dehydrogenase mutation; (b) the combined loss

184 features or genetic alterations, except for isocitrate dehydrogenase mutations (IDH(mut)) that were

185 t developments and implications in regard to isocitrate dehydrogenase mutations in chondrosarcoma, a

186 at might be relevant in cancer cells bearing isocitrate dehydrogenase mutations.

187 mRNAs and enzyme activities of the cytosolic isocitrate dehydrogenase or glucose-6-phosphate dehydrog

188 Isocitrate dehydrogenase subunits Idh1p and Idh2p were a

189 glutarate in cells results from mutations to isocitrate dehydrogenase that correlate with cancer.

190 hat specifically binds an epitope of mutated isocitrate dehydrogenase type 1 (IDH1R132H), which is fr

191 ylic acid cycle (oxoglutarate dehydrogenase, isocitrate dehydrogenase) and glycine decarboxylase.

192 ytosolic isoforms of NADP(+)/NADPH-dependent isocitrate dehydrogenase, and subsequent metabolism of g

193 hydrogenase alpha levels and lower levels of isocitrate dehydrogenase, both proteins involved in the

194 glutarate (catalyzed by reverse flux through isocitrate dehydrogenase, IDH).

195 search terms were used: IDH, IDH1, IDH2, and isocitrate dehydrogenase, in conjunction with glioma or

196 acid substrate, comprising one subfamily and isocitrate dehydrogenase, isopropylmalate dehydrogenase,

197 -(13)C]oxaloacetate to generate (13)CO(2) at isocitrate dehydrogenase, or decarboxylation of [1-(13)C

198 ein, and in the phosphorylation cycle of the isocitrate dehydrogenase, respectively.

199 rom alpha-ketoglutarate (alpha-KG) by mutant isocitrate dehydrogenase, whereas l-(S)-2-HG is generate

200 Mutations in the metabolic enzymes isocitrate dehydrogenase-1 (IDH1) and IDH2 that produce

201 Recently, it was shown that somatic isocitrate dehydrogenase-1 (IDH1) mutations, frequently

202 metabolism was highly dependent on cytosolic isocitrate dehydrogenase-1 (IDH1), because the activity

203 This isocitrate dehydrogenase-1 (IDH1)-dependent pathway is a

204 Mutations in the isocitrate dehydrogenase-1 gene (IDH1) are common driver

205 hmdC levels were independent of mutations in isocitrate dehydrogenase-1.

206 The development of acquired isocitrate dehydrogenase-1/isocitrate dehydrogenase-2 mu

207 pment of acquired isocitrate dehydrogenase-1/isocitrate dehydrogenase-2 mutations has been described

208 ticipation of concurrent NADPH sources (i.e. isocitrate dehydrogenase-2, malic enzymes, and glutamate

209 insulin secretion is amplified by cytosolic isocitrate dehydrogenase-dependent transfer of reducing

210 ive carboxylation flux through mitochondrial isocitrate dehydrogenase.

211 Isocitrate-dehydrogenase mutations (OR = 2.52, p = 0.026

212 Isocitrate dehydrogenases (IDH) convert isocitrate to al

213 scribed metabolic oncogenic factors: mutated isocitrate dehydrogenases (IDH), succinate dehydrogenase

214 Mutated isocitrate dehydrogenases (IDHs) 1 and 2 produce high le

215 Mitochondrial NAD(+)-specific isocitrate dehydrogenases (IDHs) are key regulators of f

216 e FGFR2 gene and mutations in genes encoding isocitrate dehydrogenases (in approximately 60% of iCCAs

217 Mutations in isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) have b

218 Point mutations of the NADP(+)-dependent isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) occur

219 omatic point mutations in the genes encoding isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2).

220 n the tricarboxylic acid (TCA) cycle enzymes isocitrate dehydrogenases 1 and 2 (IDH1/2) highlights th

221 tions in IDH1 and IDH2, the genes coding for isocitrate dehydrogenases 1 and 2, are common in several

222 Mutations of NADP(+)-dependent isocitrate dehydrogenases encoded by IDH1 and IDH2 occur

223 lic point mutations of the NADP(+)-dependent isocitrate dehydrogenases IDH1 and IDH2 occur frequently

224 d outcome of mutations in IDH genes encoding isocitrate dehydrogenases in adult de novo cytogenetical

225 and the expression and activity of TETs and isocitrate dehydrogenases in primary human chondrocytes.

226 Isocitrate dehydrogenases, IDH1 and IDH2, decarboxylate

227 mily as HIcDH, including isopropylmalate and isocitrate dehydrogenases, suggests all of the family me

228 expressing R172K mutant IDH2 did not display isocitrate-dependent NADPH production above vector contr

229 cells and retained the wild-type ability for isocitrate-dependent NADPH production.

230 DP(+)-dependent oxidative decarboxylation of isocitrate (ICT) to alpha-ketoglutarate (alphaKG) and th

231 e reversible NADP(+)-dependent conversion of isocitrate (ICT) to alpha-ketoglutarate (alphaKG) in the

232 NAD and isocitrate with Mg2+ binding before isocitrate in rapid equilibrium, and the mechanism appro

233 ly catalyse the oxidative decarboxylation of isocitrate into alpha-ketoglutarate (alphaKG).

234 of aconitase, which isomerizes citrate into isocitrate, is controlled by several transcriptional reg

235 tol, imidazole, uridine diphosphate glucose, isocitrate, lactate, and fucose).

236 Isocitrate lies at one of the key nodes of carbon metabo

237 Genes encoding isocitrate lyase (aceA) and malate synthase (aceB), both

238 A putative isocitrate lyase (aceA; blr2455) was among the most stro

239 nt in glyoxylate shunt enzymes, specifically isocitrate lyase (DeltaaceA) and malate synthase (Deltaa

240 We showed previously that isocitrate lyase (ICL) activity is constitutively upregu

241 sition in which the glyoxylate cycle enzymes isocitrate lyase (ICL) and malate synthase (MLS) are rep

242 Isocitrate lyase (ICL) is a peroxisomal glyoxylate cycle

243 at the first enzyme of the glyoxylate shunt, isocitrate lyase (ICL), may mediate survival of Mtb duri

244 Isocitrate lyase (ICL, types 1 and 2) is the first enzym

245 ose-1,6-bisphosphatase 1) and ICL1 (encoding isocitrate lyase 1) are under control of the Mig1 repres

246 Activity of isocitrate lyase AceA, an S-allylmercapto-modified candi

247 eling is mediated by the bifunctional enzyme isocitrate lyase acting in a noncanonical role distinct

248 ssion of the latent infection genes encoding isocitrate lyase and alpha-crystallin, respectively.

249 Enzyme assays validated the increase in isocitrate lyase and malate synthase activities.

250 In this study the genes encoding isocitrate lyase and malate synthase from Chlorogloeopsi

251 Transcript abundances for isocitrate lyase and malate synthase increased, and C. f

252 When the genes encoding isocitrate lyase and malate synthase were expressed in S

253 ve expression of the glyoxylate shunt genes (isocitrate lyase and malate synthase) was >300-fold high

254 Previous studies reported the activities of isocitrate lyase and malate synthase, the key enzymes of

255 In order to specifically address the role of isocitrate lyase and nitrogenase in chemoautotrophic gro

256 w that two additional gluconeogenic enzymes, isocitrate lyase and phosphoenolpyruvate carboxykinase,

257 mRNA for the glyoxylate cycle enzyme isocitrate lyase declined at similar rates in patients r

258 with PR genes and highest expression of the isocitrate lyase gene coinciding with highest solar irra

259 Isocitrate lyase mRNA correlated highly with CFU in sput

260 Data suggest that isocitrate lyase mRNA is a reliable marker of M. tubercu

261 Isocitrate lyase mRNA was detectable in sputum of cultur

262 three enzymes are: trace levels of OGDH, the isocitrate lyase of the glyoxylate shunt and an unantici

263 functionally novel member of the PEP mutase/isocitrate lyase superfamily and therefore targeted for

264 As with other PEP mutase/isocitrate lyase superfamily members, the protein assemb

265 ase branch of the phosphoenolpyruvate mutase/isocitrate lyase superfamily to provide insight into the

266 , a member of the phosphoenolpyruvate mutase/isocitrate lyase superfamily, catalyzes the hydrolysis o

267 at belongs to the phosphoenolpyruvate mutase/isocitrate lyase superfamily.

268 tumefaciens BlcR is a member of the emerging isocitrate lyase transcription regulators that negativel

269 Mutants of the glyoxylate shunt gene for isocitrate lyase were able to grow in the presence of oi

270 n feed into either the glyoxylate shunt (via isocitrate lyase) or the TCA cycle (via isocitrate dehyd

271 sphosphatase (FBPase), malate dehydrogenase, isocitrate lyase, and phosphoenolpyruvate carboxykinase

272 s in central carbon metabolism, specifically isocitrate lyase, malate synthase, transaldolase, fructo

273 d inhibits the growth of bacteria expressing isocitrate lyase, such as Salmonella enterica and Mycoba

274 Methylobacterium extorquens AM1, which lacks isocitrate lyase, the key enzyme in the glyoxylate cycle

275 ic acid is an organic compound that inhibits isocitrate lyase, the key enzyme of the glyoxylate shunt

276 An isocitrate lyase-deficient mutant of Mtb (Deltaicl1) exh

277 Isocitrate lyase-dependent production of succinate affor

278 all three drugs trigger activation of Mtb's isocitrate lyases (ICLs), metabolic enzymes commonly ass

279 s (Mtb) more profoundly than deletion of its isocitrate lyases (ICLs).

280 At 2 months, sputum for isocitrate mRNA correlated more closely with growth in l

281 he direction of oxidative decarboxylation of isocitrate, on the basis of initial velocity studies in

282 art on pyruvate cycling through the pyruvate/isocitrate pathway, which generates cytosolic alpha-keto

283 the oxidative decarboxylation portion of the isocitrate reaction is limiting overall.

284 c malate than with the trianionic citrate or isocitrate, suggesting that the smaller guest is better

285 dehydrogenases, IDH1 and IDH2, decarboxylate isocitrate to alpha-ketoglutarate (alpha-KG) and reduce

286 Isocitrate dehydrogenases (IDH) convert isocitrate to alpha-ketoglutarate (alpha-KG).

287 IDH1 and IDH2 to catalyze the conversion of isocitrate to alpha-ketoglutarate (alphaKG), whereas con

288 e dehydrogenase 1 (IDH1) reversibly converts isocitrate to alpha-ketoglutarate (alphaKG).

289 ich is believed to catalyze the oxidation of isocitrate to alpha-ketoglutarate in the citric acid cyc

290 ldtype function of the enzyme (conversion of isocitrate to alpha-ketoglutarate) while conferring a ne

291 bolic break at Idh, the enzyme that converts isocitrate to alpha-ketoglutarate, providing mechanistic

292 e enzyme's ability to catalyse conversion of isocitrate to alpha-ketoglutarate.

293 is prevents the oxidative decarboxylation of isocitrate to alpha-KG, and facilitates the conversion o

294 ctions, as well as the coupled conversion of isocitrate to alphaHG.

295 we have detailed the kinetics of the normal (isocitrate to alphaKG) and neomorphic (alphaKG to alphaH

296 onitase-mediated isomerization of citrate to isocitrate; trans-aconitate, but not its methyl ester, i

297 t enzyme) demonstrated half-site binding for isocitrate (two sites) in the absence of dithiothreitol

298 biomarkers-formate, citrulline, taurine, and isocitrate-were identified as markers of SSB intake.

299 ng by TamR, as do citrate, cis-aconitate and isocitrate, which are the substrate, intermediate and pr

300 rial isocitrate dehydrogenase (IDH2) to form isocitrate, which can then be isomerized to citrate.

301 ibitors, suggests random addition of NAD and isocitrate with Mg2+ binding before isocitrate in rapid